GERON CORP
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
GERN$0.97-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| NINE MONTHS ENDEDSEPTEMBER 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(54,638) | $(149,220) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 387 | 404 |
| Accretion and amortization on investments, net | (5,477) | $(7,281) |
| Amortization of debt issuance costs/debt discounts | 788 | 1,894 |
| Non-cash interest expense on liabilities for sales of future royalties | 15,043 | — |
| Stock-based compensation for services by non-employees | 70 | 122 |
| Stock-based compensation for employees and directors | 20,888 | 24,392 |
| Amortization of right-of-use assets | 542 | 501 |
| Increase in allowance for doubtful accounts | (4) | — |
| Changes in assets and liabilities: | ||
| Inventory | (56,708) | (20,283) |
| Accounts receivable, net | 589 | (28,007) |
| Prepaid expenses, interest receivable and other assets | 167 | (1,842) |
| Current and noncurrent liabilities | (114) | 4,647 |
| Payment on Royalty agreement | (10,503) | — |
| Net cash used in operating activities | (88,970) | (174,673) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (49) | (821) |
| Purchases of marketable securities | (200,202) | (292,141) |
| Proceeds from maturities of marketable securities | 286,353 | 290,469 |
| Net cash provided by (used in) investing activities | 86,102 | (2,493) |
| Cash flows from financing activities: | ||
| Proceeds from issuances of common stock from equity plans | 1,389 | 26,696 |
| Proceeds from issuance of common stock from offering and pre-funded warrant, net of paid issuance costs | — | 140,729 |
| Proceeds from exercise of warrants | — | 418 |
| Proceeds from employee stock purchase plan | 500 | 366 |
| Net cash provided by financing activities | 1,889 | 168,209 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 96 | 17 |
| Net increase in cash, cash equivalents and restricted cash | (883) | (8,940) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 80,876 | 71,138 |
| Cash, cash equivalents and restricted cash at the end of the period | $79,993 | $62,198 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.